Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Qt GROUP OYJ - Managers' Transactions

Stock Exchange Release August 13, 2020 1:00 pm ____________________________________________ Person subject to the notification requirementName: Pälsi, Mika Position: Other senior managerIssuer: QT Group OyjLEI: 743700GO2XU2ZYYDKW67 Notification type: INITIAL NOTIFICATIONReference number: 743700GO2XU2ZYYDKW67_20200813111414_3____________________________________________ Transaction date: 2020-08-12 Venue: FIRST NORTH FINLAND (FNFI)Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENTISIN: FI4000414420Nature of the transaction: DISPOSAL(

Qt GROUP OYJ - Managers' Transactions

Stock Exchange Release August 13, 2020 1:00 pm ____________________________________________ Person subject to the notification requirementName: Turunen, Tuukka Position: Other senior managerIssuer: QT Group OyjLEI: 743700GO2XU2ZYYDKW67 Notification type: INITIAL NOTIFICATIONReference number: 743700GO2XU2ZYYDKW67_20200813111537_4____________________________________________ Transaction date: 2020-08-12Venue: FIRST NORTH FINLAND (FNFI)Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENTISIN: FI4000414420Nature of the transaction: DISPOSAL

Qt GROUP OYJ - Managers' Transactions

Stock Exchange Release August 13, 2020 1:00 pm ____________________________________________ Person subject to the notification requirementName: Varelius, JuhaPosition: Chief Executive OfficerIssuer: QT Group OyjLEI: 743700GO2XU2ZYYDKW67 Notification type: INITIAL NOTIFICATIONReference number: 743700GO2XU2ZYYDKW67_20200813111744_6____________________________________________ Transaction date: 2020-08-12 Venue: FIRST NORTH FINLAND (FNFI)Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENTISIN: FI4000414420Nature of the transaction:

Photocure ASA: Invitation to presentation of second quarter and first half year 2020 financial results

Oslo, Norway, 13 August 2020: Photocure ASA (Photocure, PHO: OSE) will announce the second quarter and first half year 2020 financial results on Tuesday 18 August 2020 at 07:00 CET and invites investors, analysts and the media to a presentation at 14:00 CET the same day.The investor presentation will be streamed live and be hosted by Daniel Schneider, CEO and Erik Dahl, CFO. The presentation will be held in English and questions can be submitted throughout the event.The quarterly report and presentation will be published at 07:00 CET and will be publicly available at www.photocure.com.

Photocure appoints Genotests as exclusive partner for Hexvix[ ]in Chile

Oslo, Norway, 13 August 2020: Photocure ASA (OSE: PHO), today announced the appointment of Genotests SpA as the exclusive distributor for the commercialization of Hexvix[®] in Chile.“We are proud to take our first step into the South American continent and make Hexvix accessible to Chilean bladder cancer patients. Chile is a stable, well regulated market with a strong economy, and Genotests is well positioned to leverage their network of urologists and uro-oncologists both in the private and public hospitals”, says Dan Schneider, President and CEO of Photocure. Photocure has appointed

New Clas Ohlson store opened in Trondheim, Norway

Today at 9 am Clas Ohlson opened a new store in Sirkus Shopping, Trondheim, Norway. The area Trondheim east is growing and developing rapidly with new housing, schools and offices. Our new store in Sirkus will strengthen our presence and customer offer in this city.“Our new Sirkus store will strengthen our position in the area and give our customers increased availability to our products and services,” Rune Johansen, Operations manager Norway, explains.  Our customer offering at Sirkus shopping also includes Click & Collect for a fast and simple customer experience. The online order is

KEBNI STRENGTHENING LEADERSHIP FOR LAND MOBILE

KebNi is hiring Erik Wiberg as Managing Director for its Land Mobile business. Erik Wiberg has extensive sales and operational experience from the satellite communication industry.KebNi is strengthening its leadership by the recruitment of Erik Wiberg in a new position as Managing Director for its Land Mobile business. Land Mobile covers both "Comms on the Move" acquired earlier in the year from ReQuTech and Satmission solutions. Erik Wiberg has a diverse and global background within the telcom and satcom industries. He has 18 years of experience in the satcom industry with positions

Vicore Pharma publishes a prospectus for admission to trading of shares on Nasdaq Stockholm in connection with a directed share issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA,  CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND,  THE UNITED KINGDOM , THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION WHERE THE PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION MEASURES OR ANY OTHER MEASURE UNDER APPLICABLE LAW. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO, OR INVITATION TO, ACQUIRE OR SUBSCRIBE FOR ANY FINANCIAL INSTRUMENTS IN VICORE PHARMA IN ANY JURISDICTION.Gothenburg, August 13, 2020 – The board of

Södra strengthens its work within public affairs

Marcus Svensson has been appointed Head of Public Affairs at Södra. He will organise, coordinate and manage Södra’s work within public affairs going forward.“Our industrial operations and terms for forest ownership are largely dependent on external decisions taken by the authorities and politicians. During the last few years, we have seen issues concerning sustainability, fossil-fuel independence and a circular economy as well as ownership, use and forest products rise in importance on the agenda at national as well as EU level. This is a development we are now addressing by strengthening

Lipum prepares for LSX Nordic Virtual event

News: Umeå, 13 August 2020. Lipum participate in LSX Nordic Viritual event 1-4 September.LSX is a community of senior life science decision makers where they connect senior life science executives with the capital, intelligence, innovation, and partners the companies need to grow their businesses. “Through these conferences and networking events we have the possibility to share our progress and hopefully reach out to investors and industry stakeholders. It´s a perfect arena for Lipum”, says Einar Pontén, CEO.

CELLINK announces strategic partnership with Carcinotech to advance 3D-bioprinting technology for cancer research

CELLINK, a leading provider of innovative biomaterials and technologies for 3D bioprinting applications in the life sciences, announced a collaboration with Carcinotech, which focuses on the production of cancer research models for drug testing, cancer drug discovery and the study of cancer biology. This collaboration seeks to use CELLINK’s patent-pending bioinks to help Carcinotech develop its proprietary 3D-bioprinted cancer research model that will mimic cancer systems found in the human body on a micro-size chip. One of the biggest challenges in cancer drug testing and treatments

Gapwaves receives antenna prototype order from global tech giant

Gapwaves, a Sweden-based company with patented technology for millimeter wave waveguide antennas, today announced an order for 77 GHz antenna prototypes from a global tech giant. The order is for test and evaluation purposes with expected delivery during Q3 2020 and a value of ca 1.5 MSEK.Gapwaves CEO Lars-Inge Sjöqvist comments: ”We are very excited about this order and the opportunity to present Gapwaves waveguide technology. Our customer is a true leader in technology innovation and we are very enthustiastic to provide a waveguide antenna representing high performance and compact form

FluoGuide A/S and LI-COR Biosciences sign agreement to develop uPAR targeted products to guide oncology surgery using LI-COR’s proprietary next-generation fluorophore IRDye 800CW

Copenhagen, Denmark, 13 August 2020 – FluoGuide A/S (“FluoGuide” or “the Company”) has signed a non-exclusive supply and licensing agreement with the US company LI-COR Biosciences. The agreement will help FluoGuide broaden its portfolio of uPAR-targeted products with features unique to IRDye 800CW, such as deep tissue targeting. With this latest agreement, FluoGuide is well-positioned to maximize the clinical and commercial potential of uPAR-targeted products in fluorescent-guided surgery for cancer.FluoGuide’s strategic development plan centers on advancing its lead product, FG001, for

Invitation to Latour’s presentation of the half year report for 2020

Latour will publish the interim report for the second quarter on 20 August, 2020 at 08.30 AM (CEST). President and CEO Johan Hjertonsson will present the report and answer to questions together with CFO Anders Mörck on the same day at 10.00 AM (CEST) in a webcasted telephone conference. To participate in the meeting and be able to ask questions, please call +46 (0)8 505 583 58To follow the webcast please use the link: https://onlinexperiences.com/Launch/QReg/ShowUUID=5F0B3FD3-8873-451B-875D-FD02D4A6E504 Göteborg, August 13, 2020 INVESTMENT AB LATOUR (PUBL)Johan Hjertonsson,

Fortum initiates an Environmental Impact Assessment procedure for Loviisa nuclear power plant

FORTUM CORPORATION PRESS RELEASE 13.8.2020   Fortum [Power and Heat Oy] has initiated an Environmental Impact Assessment procedure (EIA procedure) for the Loviisa nuclear power plant. The procedure will assess the environmental impacts of a potential extension of the operation of the power plant or, alternatively, the decommissioning of the power plant, as well as the environmental impacts of the final disposal facility for low- and intermediate-level waste.  “Loviisa power plant’s current operating licenses are valid until the end of 2027 and 2030. In this procedure, we will

Invitation to Tobii’s Earnings Call Following the Second Quarter of 2020

Tobii AB plans to publish the interim report for the period January 1-June 30, 2020 on August 19 at 7.30 a.m. CET. Following this report, at 10.00 a.m. CET, Tobii will host a conference call with web cast presentation for investors, analysts and media. Tobii’s President and CEO Henrik Eskilsson and CFO Johan Wilsby will present and comment on the report. After the presentation, there will be time for questions. The presentation will be held in English. Conference call · Time: Wednesday August 19, 2020, 10.00 a.m. CET · Phone numbers: Sweden                          +46 (0)

Contract for CSV Normand Vision with Ocean Installer

Solstad Offshore ASA has been awarded a contract with Ocean Installer for the CSV Normand Vision. The contract commences in 1Q and the firm and optional periods covers the majority of 2021. Normand Vision is a high capacity Construction Support Vessel designed and built for installation of Subsea Structures, Umbilicals, Risers and Flowlines (SURF). The vessel was delivered in 2014 and has worked for Ocean Installer most of the time since then.   Skudeneshavn, August 13[th], 2020 ContactsLars Peder Solstad CEO, at +47 91 31 85 85Kjetil Ramstad CFO, at +47 90 75 94 89 Solstad

Höegh LNG: Webcast/Q&A session details for the second quarter and first half of 2020 financial results

Hamilton, Bermuda, 13 August 2020 - Höegh LNG Holdings Ltd. ("Höegh LNG") will release its financial results for the quarter and half year ended 30 June 2020 on Thursday 20 August 2020 at 07:00 am CET. In connection with this, Höegh LNG will hold a webcast at 09:00 am CET which will immediately be followed by a Q&A session. The webcast can be accessed through the following channels:   · · Via "Investor relations" on Höegh LNG's website www.hoeghlng.com, or the following link: https://channel.royalcast.com/webcast/hegnarmedia/20200820_5/ · By dialling +47 2100 2610 (Oslo), +44 (0)

Invitation to a conference call and webcast by Isofol in connection with the entered license agreement with Solasia

GOTHENBURG, Sweden, August 13, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) has today announced that it entered into a license agreement with Solasia Pharma K.K (“Solasia”) (TSE: 4597), to develop and commercialize Isofol’s proprietary late-stage drug candidate arfolitixorin in Japan. In connection with this, Isofol invites investors, analysts and media to a conference call and webcast on August 13, 2020 at 11:00 (CEST).The presentation will be held by CEO Ulf Jungnelius in English and will conclude with a Q&A session. Questions can be asked

2020 Bulkers Ltd. (2020) – Commercial update and key information relating to the dividend for July 2020.

Hamilton, Bermuda, August 13, 2020 Commercial update: In July 2020, the Company achieved average time charter equivalent earnings of approximately US$23,200 per day, gross. The Company’s two vessels trading on index-linked time charter earned approximately US$35,200 per day, gross, including average daily scrubber benefits of approximately US$1,400 per day. The Company’s six vessels trading on fixed time charter earned approximately US$19,300 per day, gross, including average daily scrubber benefits of approximately US$1,400 per day for two of the vessels. The Baltic 5TC Capesize

Evolution selected for PointsBet US Live Casino rollout

[PR] Evolution Gaming, leading provider of Live Casino solutions, announced today that it has been selected by PointsBet, a premier global sportsbook operator, for its rollout of Live Casino services in the US online gambling market.Originally founded in Australia, PointsBet is currently operational in New Jersey, Indiana, and Iowa, offering both online and land-based sports betting. PointsBet entered the US market in July 2018 when it gained a commercial licence to operate as an online corporate bookmaker in New Jersey and commenced taking bets in the Garden State in January 2019. Since

Isofol enters licensing agreement with Solasia to develop and commercialize arfolitixorin in Japan

GOTHENBURG, Sweden, August 13, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) today announced that it entered into a license agreement with Solasia Pharma K.K (“Solasia”) (TSE: 4597), a specialized oncology company headquartered in Japan, to develop and commercialize Isofol’s proprietary late-stage drug candidate arfolitixorin in Japan. Under the terms of the agreement, Isofol will receive a total amount of ~$ 100 million* (SEK 890 million*) as upfront, development, regulatory and sales-based milestone payments and clinical development cost. In

There are no items matching the current filter
There are no more items matching the current filter
Back to top